Acadian Asset Management
PGNX

Acadian Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Acadian Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-282,701
Closed -$2.67M – 1685
2017
Q1 		$2.67M Buy
+282,701
New +$2.82M 0.01% 547
2016
Q1 		– Sell
-438,402
Closed -$2.69M – 1543
2015
Q4 		$2.69M Buy
438,402
+117,995
+37% +$774K 0.01% 524
2015
Q3 		$1.83M Buy
320,407
+316,841
+8,885% +$2.43M 0.01% 566
2015
Q2 		$27K Buy
3,566
+276
+8% +$1.67K ﹤0.01% 1076
2015
Q1 		$20K Buy
+3,290
New +$20.7K ﹤0.01% 1123

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Acadian Asset Management's PGNX Position: Q2 2017 in Review

Acadian Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2017, closing a stake of 282,701 shares — an estimated $2.67M sold.

Acadian Asset Management first reported a position in PGNX in Q1 2015 and held it in 5 quarters. The position peaked at $2.69M in Q4 2015. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • Acadian Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Acadian Asset Management sold 282,701 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $2.67M.
  • Acadian Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 5 quarters.
  • Acadian Asset Management's Progenics Pharmaceuticals Inc position peaked at $2.69M in Q4 2015.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on Acadian Asset Management's 13F filing for Q2 2017, filed 25 Jul 2017.